(Reuters) – AstraZeneca Plc said on Wednesday China’s health regulator has approved Tagrisso, the British drugmaker’s lung cancer treatment, as adjuvant treatment for patients with an early-stage lung cancer.
The drugmaker said the approval by China’s National Medical Products Administration (NMPA) was based on positive results from a late-stage trial.
The lung cancer drug was approved in the United States for a similar indication in December 2020.
(Reporting by Vishwadha Chander in Bengaluru; Editing by Shailesh Kuber)
